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Colicin A enters Escherichia coli cells through interaction with endogenous TolA and TolB proteins.
In vitro, binding of the colicin A translocation domain to TolA leads to unfolding of TolA. Through
NMR studies of the colicin A translocation domain and polypeptides representing the individual
TolA and TolB binding epitopes of colicin A we question if the unfolding of TolA induced by colicin
A is likely to be physiologically relevant. The NMR data further reveals that the colicin A binding site
on TolA is different from that for colicin N which explains why there is a difference in colicin toxicity
for E. coli carrying a TolA-III homologue from Yersina enterocolitica in place of its own TolA-III.
Structured summary:
MINT-7888512: TolA (uniprotkb:P19934) and Col-A (uniprotkb:P04480) bind (MI:0407) by nuclear
magnetic resonance (MI:0077)
MINT-7888526: TolA (uniprotkb:P19934) and TolB (uniprotkb:P0A857) bind (MI:0407) by nuclear
magnetic resonance (MI:0077)
MINT-7888999: TolA (uniprotkb:P19934), TolB (uniprotkb:P0A855) and Col-A (uniprotkb:P04480)
physically interact (MI:0915) by molecular sieving (MI:0071)
MINT-7888982: TolA (uniprotkb:P19934), TolB (uniprotkb:P0A855) and Col-A (uniprotkb:P04480)
physically interact (MI:0915) by nuclear magnetic resonance (MI:0077)
 2010 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Colicins are plasmid-encoded bacterial proteins that kill suscep-
tible bacteria [1]. Separate domains recognise an outer-membrane
protein of the target cell that is the initial colicin-binding receptor
(the R-domain), help translocate the colicin into the target cell (the
T-domain) and kills the target cell [2]. One common mechanism of
cell-killing involves formation of a pore in the inner membrane of
the target cell [1,2], which is how both colicins N and A kill suscep-
tible cells [1]. Colicins N and A enter E. coli cells with the assistance
of TolA, an endogenous protein in the target cell where it spans the
periplasm helping to maintain outer membrane integrity [3]. The
N-terminal domain of TolA is anchored in the inner membrane
with the C-terminal domain (TolA-III), which interacts with colic-
ins N and A, attached to a stalk that places it close to the inner sur-
face of the outer membrane [4]. The binding epitopes for TolA-III
are carried in the N-terminal domains of colicins N and A which
are believed to be intrinsically disordered [5,6]. Colicin A (ColA),
but not colicin N (ColN), also needs TolB, an endogenous partner
of TolA, for translocation into the target cell [2]. The TolB bindingon behalf of the Federation of Euroepitope of ColA is also located in its translocation domain (Fig. 1)
[7].
Filamentous phages also use TolA-III to access target cells but
their interaction with it involves a globular domain, g3p, and not
a disordered domain [8]. When either g3p or the T-domain of ColN
binds to TolA-III, the bound TolA-III retains its secondary structure
elements and global fold [9,10]. In contrast, binding of the ColA
T-domain has been reported to cause dramatic conformational
changes in TolA-III consistent with its partial unfolding, suggesting
that ColA parasitizes E. coli by a different mode of action than ColN
and bacteriophages [5]. We set out to investigate the origin of this
difference between colicins N and A with multinuclear NMR spec-
troscopy. Our initial results conﬁrm that in vitro the T-domain of
ColA at least partially unfolds TolA-III [10], but we also present evi-
dence here that a ColA sub-domain constituting just the TolA bind-
ing epitope does not unfold TolA-III.
2. Materials and methods
2.1. Protein expression, puriﬁcation and sample preparation
Samples of TolA-III comprising amino acids 296-421 of the
E. coli TolA protein (Swiss-Prot accession number P19934) werepean Biochemical Societies.
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Fig. 1. Domain structure of ColA depicting its three functional domains: translo-
cation domain (T-domain) (cross-hatched, TolB epitope; diamonds, TolA epitope),
receptor binding domain (black, R-domain), and pore-forming domain (white, P-
domain).
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produced as described previously using plasmid pRJ379 [12]. Isoto-
pically labelled samples were obtained from cells grown in M9
minimal medium containing 1 g/l 15NH4Cl as the only nitrogen
source and, where appropriate, 4 g/l [13C6] glucose as the sole car-
bon source. Protein concentrations were determined from UV
absorption at 280 nm [13].
The T-domain peptides of ColA were prepared from expression
systems constructed using E. coli DH5a as the host strain for clon-
ing and mutagenesis and E. coli BL21 (DE3) (Novagen) as the host
strain for the expression vector pET21a (Novagen). Plasmid
pTA107, which encodes the ﬁrst N-terminal 107 residues of ColA
with a C-terminal His-tag, under the control of an inducible T7 pro-
moter has been previously described [7]. Plasmid pYZ69 was de-
rived from pTA107 by engineering a thrombin recognition site
(LeuValProArgGlySer) after residue 52 in the TA107 protein.
2.2. NMR spectroscopy
NMR spectra were acquired at the indicated temperatures using
a Bruker Avance III 800 MHz spectrometer equipped with a triple
resonance probe and pulse sequences incorporated into the Bruker
Topspin 2.1 software. All protein samples were in 50 mM phos-
phate buffer pH 6.8 containing 300 mM NaCl and 7.5% 2H2O.
Unlabelled TolB was stepwise titrated into a sample of 13C/15N
labelled TolA-III (0.2 mM) to reach TolB:TolA-III molar ratios of
0.5:1, 1:1 2:1 and 4:1, and the shifts of resonances were followed
by recording 1H–15N HSQC spectra after each titration step at
10 C, 27 C and at 35 C. Thereafter, unlabelled ColA1–107 was step-
wise titrated into the sample of 13C/15N labelled TolA-III in com-
plex with unlabelled TolB to reach a molar ratio of 1 TolA-III to 4
TolB and 6 ColA1–107 and the shifts of resonances were followed
with 1H–15N HSQC spectra at 35 C. Samples containing all three
proteins were subjected to size exclusion chromatography on a
superdex S75 column using the same buffer as in the NMR exper-
iment, but without 2H2O. The fractions containing the trimeric
complex (as veriﬁed by PAGE and MS) were concentrated and
1H–15N HSQC spectra acquired. Unlabelled ColA53–107 was stepwise
titrated into a sample of 13C/15N labelled TolA-III (0.3 mM) to reach
ColA53–107:TolA-III molar ratios of 0.5:1, 1:1 and 5:1, and the reso-
nance shifts followed with 1H–15N HSQC spectra. Similarly, unla-
belled ColA1–52 was stepwise titrated into a sample of 13C/15N
labelled TolA-III (0.3 mM) in complex with unlabelled ColA53–107
(0.45 mM) to reach a molar ratio of TolA-III–TolB:ColA53–107 of
1:1 and 1:2, 1:3, 1:5, 1:10 with 1H–15N HSQC spectra recorded
after each titration step.
Resonance assignments of 13C/15N labelled TolA-III (0.6 mM) in
complex with unlabelled ColA53–107 (1 mM) were obtained from
1H–15N HSQC, CBCA(CO)NH, HNCACB and HNCA spectra at 27 C.NMR spectra were processed using NMRPipe [14] and analysed
in NMRView [15] as described previously [10]. NH chemical shift
variations were calculated using the formula: {(DdH)2 +
(cN/cH * DdN)
2}2.
3. Results and discussion
3.1. The T-domain of colicin A unfolds TolA-III in vitro
1H–15N HSQC spectra of 13C/15N labelled TolA-III to which unla-
belled ColA1–107 had been added were consistent with partial
unfolding of TolA-III [10] (Supplementary Fig. 2) as previously de-
scribed by Deprez et al. for ColA1–172 [5]. Previous reports of the
interaction between ColA and TolA-III have used ColA T-domain
containing both the binding epitopes for TolA as well as TolB and
were conducted in the absence of TolB [5,10]. We investigated
whether binding of the ColA T-domain leads to the unfolding of
TolA-III in the presence of TolB. We ﬁrst titrated unlabelled TolB
into a sample of 13C/15N-labelled TolA-III, which resulted in broad-
ening of almost all the 1H–15N HSQC resonances that had been as-
signed to backbone NH groups of the globular domain of TolA-III
[10,16], leaving only NH resonances of the more ﬂexible parts of
TolA-II/TolA-III visible (Supplementary Fig. 2). This result indicates
the formation of the TolB:TolA-III complex. We next investigated
whether ColA1–107 has the same effect on TolA-III when TolB is pres-
ent as it has when TolB is absent. We added unlabelled ColA1–107 to
13C/15N-labelled TolA-III bound to unlabelled TolB. Although this
results in an even larger complex it would be expected that sharp
amide resonances with a narrow 1H chemical shift dispersion
would appear if binding of the ColA T-domain led to unfolding of
TolA-III, but this was not the case (Supplementary Fig. 3). The exis-
tence of a trimeric complex between TolB, TolA-III and ColA1–107
was conﬁrmed by gel ﬁltration and MS (Supplementary Fig. 4).
Thus, it is possible that it is the unoccupied TolB binding epitope
that causes unfolding of TolA-III in the ColA1–107:TolA-III complex
and not simply binding of TolA-III to the TolA epitope of colicin A.
3.2. The separate TolA and TolB binding peptides do not unfold TolA-III
Having established that the in vitro unfolding of TolA-III by
ColA1–107 only occurs when ColA1–107 is not bound to TolB we set
out to study the interaction between TolA-III and the ColA TolA
binding epitope separated from the TolB binding epitope. For this
purpose we made a construct of the ColA T-domain containing a
thrombin cleavage site after residue Met 52, thus separating the
TolA site (ColA53–107) from the TolB site (ColA1–52) (Fig. 1).
Titration of unlabelled ColA53–107 into a sample of 13C/15N la-
belled TolA-III resulted in the shift of about half of the TolA-III back-
bone NH resonances, many of them shifted only slightly, (Fig. 2)
without the extreme changes associatedwith unfolding. This shows
that ColA53–107 interacts with TolA-III without unfolding TolA-III.
The addition of unlabelled ColA1–52 to the TolA-III:ColA53–107 com-
plex containing 15N-TolA-III did not change the TolA-III spectrum
(data not shown) showing it neither bound to TolA-III nor unfolded
it.
3.3. The colicin A binding region of TolA-III is different from that for
colicin N and g3p
We next wanted to map the ColA binding site of TolA-III and ti-
trated unlabelled ColA53–107 into 13C/15N labelled TolA-III. As the
complex is in slow exchange on the NMR timescale we used triple
resonance NMR to assign the ColA53–107 bound state of TolA-III. Of
the 76 residues of TolA-III for which resonances have been as-
signed in the unbound state [10] resonances of 71 residues could
be assigned unambiguously in the ColA53–107 bound state of
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Fig. 2. Overlay of an 800 MHz 1H–15N HSQC spectra of 13C/15N labelled TolA-III (black) and TolA-III in complex with unlabelled ColA53-107 (red).
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Fig. 3. Overlay of the NH chemical shift variations between the free and the
ColA53–107 bound form of TolA-III (black) and the free and the ColN T-domain bound
form of TolA-III as published by Hecht et al. [10] (red).
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complex with ColA53–107 are shown in Fig. 3 in comparison with
the chemical shift perturbations of TolA-III interacting with the
colicin N T-domain [10]. The TolA-III perturbations are greater with
ColN, and with g3p [9], than with ColA suggesting that the ColA
TolA-III interaction is not accompanied by conformational changes
in the way described for the other TolA-III interactions [9,10]. Fig. 4
shows the TolA-III chemical shift perturbations caused by ColA53–107
binding mapped onto the solution structure of TolA-III in compar-
ison with similar data for ColN [10] and g3p [9]. Although some
areas of the interactions are common for all three, indicating over-
lapping binding sites, there are signiﬁcant differences; for example,the TolA-III area between residue M39 and K44 that is most af-
fected by ColA is not affected by ColN (Fig. 3). These differences
are signiﬁcant when viewed in the context of the report of Weitzel
and Larsen [17]. It shows that an E. coli TolA-III homologue from
Yersina enterocolitica supported the physiological function of the
Tol system in E. coli, conferring sensitivity to the TolA dependent
colicins A, K and E1 but not to ColN. Fig. 4 indicates the residues
in the Y. enterocolitica TolA-III homologue different from those in
E. coli TolA-III (red); only one residue of these is strongly affected
by ColA binding whilst eight are strongly affected by ColN. We pre-
viously pointed out the striking similarity between the ColN–TolA-III
and the g3p–TolA-III interaction [10] and in Fig. 4 highlight the
TolA-III residues that are in contact with g3p in the g3p–TolA-III
crystal structure [8] (distance <4.5 Å) (yellow). These residues are
also likely to be part of the ColN binding site and it is apparent that
almost half of these residues are different in the Y. enterocolitica
TolAIII homologue.
3.4. Possible physiological relevance
With all in vitro biochemical investigations of complex biologi-
cal systems there can be uncertainty about how relevant observa-
tions are to the in vivo situation. The data presented here are not
an exception to this. It is nevertheless signiﬁcant that we have
established that although the T-domain of ColA at least partially
unfolds its co-receptor TolA-III in vitro, as ﬁrst reported by Deprez
et al. [5], the unfolding results from the absence of TolB binding to
ColA. When TolB is present, or when the TolA and TolB binding epi-
topes are separated then TolA-III is not unfolded. This means all
characterised colicin interactions with TolA-III have the common
feature that the TolA-III remains structured, and whilst there are
differences in the binding sites on TolA-III for different colicins
they do overlap. The observation that ColA1–107 perturbs the fold
of TolA-III but that neither ColA1–52 or ColA53–107, alone or together,
lead to its unfolding is intriguing. One possibility is that when
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Fig. 4. (Upper panel) NH chemical shift variations between the free and the ColA53–107 bound form of TolA-III (left), between the free and the colicin N T-domain bound [10]
form of TolA-III (middle), and between the free and the g3p bound [9] form of TolA-III (right). Chemical shift variations greater than 0.14 ppm (salmon) and 0.2 ppm (red)
(left) and greater than 0.4 ppm (salmon) and 0.55 ppm(red) (middle and right) [19] respectively are mapped onto the solution structure of TolA-III [9]. (Lower panel)
Comparision of the Yersinia enterocolitica tola gene [17] and its predicted product with the Escherichia coli homologue [19] as shown by Weitzel and Larsen [17]. The helical
(bars) and beta strand (arrows) regions are depicted as present in the solution structure of TolA-III [9]. Residues in the sequence of Y. enterocolitica that are different from the
sequence of E.coli are shown in red letters. Chemical shift perturbations stronger than 0.2 ppm are indicated as black (upon ColA53–107 interaction) and red (upon ColN
T-domain interaction) bars. TolA-III residues that are in contact with g3p in the g3p–TolA-III crystal structure are highlighted in yellow [8].
2252 O. Hecht et al. / FEBS Letters 584 (2010) 2249–2252TolA-III is bound to its site between residues 53 and 107 in
ColA1–107, the attached region from 1–52 also binds to TolA-III
and it is this interaction that leads to the unfolding. This is similar
to the self-recognition we have reported for the T-domain of ColN
in the absence of its partner TolA-III, which we suggested is in-
duced because the linear binding epitope is hydrophobic and its
exposure to water is energetically unfavourable [6]. Such a model
explains why the presence of TolB would protect TolA-III from
being unfolded by ColA1–107 as the TolB would occupy the TolB
binding site in preference to it interacting with TolA-III. It remains
to be established whether the ColA T-domain unfolds TolA-III in
vivo, though our view is that this is unlikely to be signiﬁcant be-
cause although the TolB–TolA association may be of a transient
nature, there is an excess of TolB over TolA in the periplasm [18]
and as Cascales et al. [2] suggest in their comprehensive review,
the Tol proteins interact to form a stoichiometric complex.
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